Allogenic Therapies

We are interested in biotechs exploring diverse cell types with limited immunogenic profiles that may be more suitable for off-the-shelf treatments, including emerging approaches such as virus-specific T cells, NK cells, and macrophages. Alongside new cell types, we are interested in start-ups focused on optimizing and automating in-house manufacturing processes that will scale the production of approved cell therapies in the future and avoid manufacturing delays that affect CAR T-cells. Existing cell therapies have struggled to address solid tumors and still carry risks of toxic immune responses. We are targeting start-ups seeking to improve the binding specificity and persistence of cell therapies using high-throughput screening techniques to identify the next generation of improved CAR constructs for tumor cell targeting.